325 related articles for article (PubMed ID: 24750361)
1. Systemic inflammation in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention.
Zhang XL; Chi YH; Wang le F; Wang HS; Lin XM
Respirology; 2014 Jul; 19(5):723-9. PubMed ID: 24750361
[TBL] [Abstract][Full Text] [Related]
2. Impact of chronic obstructive pulmonary diseases on outcomes and hospital days after percutaneous coronary intervention.
Zhang JW; Zhou YJ; Yang Q; Yang SW; Nie B; Xu XH
Angiology; 2013 Aug; 64(6):430-4. PubMed ID: 22942128
[TBL] [Abstract][Full Text] [Related]
3. Impact of high-sensitivity C-reactive protein on coronary artery disease severity and outcomes in patients undergoing percutaneous coronary intervention.
Liu Y; Jia SD; Yao Y; Tang XF; Xu N; Jiang L; Gao Z; Chen J; Yang YJ; Gao RL; Xu B; Yuan JQ
J Cardiol; 2020 Jan; 75(1):60-65. PubMed ID: 31416781
[TBL] [Abstract][Full Text] [Related]
4. Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study).
Pan HC; Sheu WH; Lee WJ; Lee WL; Liao YC; Wang KY; Lee IT; Wang JS; Liang KW
Clin Chim Acta; 2015 May; 445():93-100. PubMed ID: 25818243
[TBL] [Abstract][Full Text] [Related]
5. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention.
Shitara J; Ogita M; Wada H; Tsuboi S; Endo H; Doi S; Konishi H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Miyauchi K; Daida H
J Cardiol; 2019 Jan; 73(1):45-50. PubMed ID: 30001869
[TBL] [Abstract][Full Text] [Related]
7. Association of baseline C-reactive protein levels with periprocedural myocardial injury in patients undergoing percutaneous bifurcation intervention: a CACTUS study subanalysis.
Niccoli G; Sgueglia GA; Latib A; Crea F; Colombo A;
Catheter Cardiovasc Interv; 2014 Jan; 83(1):E37-44. PubMed ID: 23813627
[TBL] [Abstract][Full Text] [Related]
8. [Association between high-sensitivity C-reactive protein and contrast-induced nephropathy after primary percutaneous coronary intervention].
He YT; Tan N; Liu YH; Chen SQ; Liu Y; Huang SJ; Yang DH; Ye P; Ran P
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 May; 41(5):394-8. PubMed ID: 24021122
[TBL] [Abstract][Full Text] [Related]
9. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.
Akpek M; Kaya MG; Lam YY; Sahin O; Elcik D; Celik T; Ergin A; Gibson CM
Am J Cardiol; 2012 Sep; 110(5):621-7. PubMed ID: 22608360
[TBL] [Abstract][Full Text] [Related]
10. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
[TBL] [Abstract][Full Text] [Related]
11. Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT Study).
Kelly CR; Weisz G; Maehara A; Mintz GS; Mehran R; Lansky AJ; Parise H; de Bruyne B; Serruys PW; Stone GW
Am J Cardiol; 2014 Aug; 114(3):376-83. PubMed ID: 24931291
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention.
Ndrepepa G; Braun S; Cassese S; Fusaro M; King L; Kastrati A; Schmidt R
Cardiovasc Revasc Med; 2013; 14(5):264-9. PubMed ID: 23969223
[TBL] [Abstract][Full Text] [Related]
13. Markers of low-grade inflammation and soluble cell adhesion molecules in Chinese patients with coronary artery disease.
Fang L; Wei H; Mak KH; Xiong Z; Song J; Wang D; Lim YL; Chatterjee S
Can J Cardiol; 2004 Dec; 20(14):1433-8. PubMed ID: 15614337
[TBL] [Abstract][Full Text] [Related]
14. Impact of Combined C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels on Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention.
Ogita M; Miyauchi K; Tsuboi S; Shitara J; Endo H; Wada H; Doi S; Naito R; Konishi H; Dohi T; Kasai T; Tamura H; Okazaki S; Suwa S; Daida H
Am J Cardiol; 2015 Oct; 116(7):999-1002. PubMed ID: 26243577
[TBL] [Abstract][Full Text] [Related]
15. [Predictive value of fibrinogen and high-sensitivity C-reaction protein for cardiovascular events in patients with stable coronary artery disease].
Huang W; Chen QW; Lei H; Deng W; Ke DZ
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Aug; 34(8):718-21. PubMed ID: 17081398
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris.
Gach O; Legrand V; Biessaux Y; Chapelle JP; Vanbelle S; Pierard LA
Am J Cardiol; 2007 Jan; 99(1):31-5. PubMed ID: 17196457
[TBL] [Abstract][Full Text] [Related]
17. High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention.
Shacham Y; Leshem-Rubinow E; Steinvil A; Keren G; Roth A; Arbel Y
Clin Exp Nephrol; 2015 Oct; 19(5):838-43. PubMed ID: 25492251
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome.
Sukhija R; Fahdi I; Garza L; Fink L; Scott M; Aude W; Pacheco R; Bursac Z; Grant A; Mehta JL
Am J Cardiol; 2007 Apr; 99(7):879-84. PubMed ID: 17398176
[TBL] [Abstract][Full Text] [Related]
19. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
[TBL] [Abstract][Full Text] [Related]
20. Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention.
Wang JN; Yan YY; Guo ZY; Jiang YJ; Liu LL; Liu B
Chin Med J (Engl); 2016 Dec; 129(23):2786-2791. PubMed ID: 27900989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
